BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 22038350)

  • 1. In Vitro Effects of Papaverine on Cell Migration and Vascular Endothelial Growth Factor in Cancer Cell Lines.
    Gomes DA; Joubert AM; Visagie MH
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of CXCL17 increases migration and invasion of A549 lung adenocarcinoma cells.
    Koni E; Congur I; Tokcaer Keskin Z
    Front Pharmacol; 2024; 15():1306273. PubMed ID: 38384293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 14-3-3 protein induction on cell proliferation of A549 human lung adenocarcinoma.
    Kawamoto S; Iemura N; Inoue Y; Katakura Y; Shirahata S
    Cytotechnology; 2000 Jul; 33(1-3):253-7. PubMed ID: 19002833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute cytotoxicity and increased vascular endothelial growth factor after in vitro nitrogen mustard vapor exposure.
    McGraw MD; Kim SY; White CW; Veress LA
    Ann N Y Acad Sci; 2020 Nov; 1479(1):223-233. PubMed ID: 32408394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy.
    Carter JG; Gammons MV; Damodaran G; Churchill AJ; Harper SJ; Bates DO
    Angiogenesis; 2015 Jan; 18(1):23-30. PubMed ID: 25274272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between CHRNA3 rs1051730 genotype and lung cancer risk in Chinese Han population: a case-control study.
    Ren JH; Jin M; He WS; Liu CW; Jiang S; Chen WH; Yang KY; Wu G; Zhang T
    J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):897-901. PubMed ID: 24337855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of siRNA targeting MTA1 on metastasis malignant phenotype of ovarian cancer A2780 cells.
    Rao YM; Ji M; Chen CH; Shi HR
    J Huazhong Univ Sci Technolog Med Sci; 2013 Apr; 33(2):266-271. PubMed ID: 23592142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of exogenous VEGF(165)b on invasion and migration of human lung adenocarcinoma A549 cells.
    Chen J; Li Z; Zhang S; Zhang R; Dassarath M; Wu G
    J Huazhong Univ Sci Technolog Med Sci; 2011 Oct; 31(5):619. PubMed ID: 22038350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
    Zhu F; Zhang Z; Wu G; Li Z; Zhang R; Ren J; Nong L
    Med Oncol; 2011 Jun; 28(2):565-71. PubMed ID: 20300976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549.
    Li ZY; Zhu F; Hu JL; Peng G; Chen J; Zhang S; Chen X; Zhang RG; Chen LJ; Liu P; Luo M; Sun ZH; Ren JH; Huang LL; Wu G
    Tumour Biol; 2011 Aug; 32(4):677-87. PubMed ID: 21442281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tetraspanin CD151 inhibition on A549 human lung adenocarcinoma cells.
    Li P; Zeng H; Qin J; Zou Y; Peng D; Zuo H; Liu Z
    Mol Med Rep; 2015 Feb; 11(2):1258-65. PubMed ID: 25351816
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.